If you didn't find what you were looking for, try a new search!
This summary gives a broad overview of the main themes discussed at the 5th International Conference on FMR1 Premutation in early 2023.
For 40 years, the NFXF has been an essential resource, assisting families living with Fragile X across their lifespan, as well as the professionals who strive to serve them throughout their careers.
Archived conference materials from the 2022 18th International Fragile X Conference in San Diego, Calif., July 14-17.
Reproductive Health and Your Options There is no one way to grow a family. Whether you know you carry a gene that can be passed on to your future children and want to explore [...]
Educational strategies are not just helpful for school-aged children! The one-hour Q&A panel discussion, moderated by Hilary Rosselot, includes panelists with expertise and suggestions to support individuals living with Fragile X throughout the lifespan!
One of the most exciting advancements being done in Fragile XS research today is antisense oligonucleotide (ASO) therapy.
The Kelleher Lab at Purdue University is conducting an NIH-funded clinical trial called Project WellCAST. Project WellCAST aims to understand how to best support caregivers of children with rare neurogenetic conditions, including Fragile X syndrome.
Dr. Connor Maltby, a 2022 Jr. Investigator, summarizes the Fragile X Premutation panel discussion at the NFXF's 18th International Fragile X Conference.
Dr. Kate Shelly, a 2022 Jr. Investigator, summarizes the Research Landscape panel at the NFXF's 18th International Fragile X Conference.
Dr. Carolyn Yrigollen summarizes the Fragile X Premutation Basic Science Research session at the NFXF's 18th International Fragile X Conference.
